Inhibrx, Inc. (INBX)

34.62 +0.18 (+0.52%) As of 11:04AM EDT. Market open.

Inhibrx, Inc.

11025 North Torrey Pines Road
Suite 200 Torrey Pines Science Park
La Jolla, CA 92037
United States
858 795 4220
https://inhibrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 166

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark Paul Lappe	Founder, Chairman, President & CEO	1.1M	N/A	1967
Dr. Brendan P. Eckelman Ph.D.	Founder & Chief Scientific Officer	769.25k	N/A	1979
Ms. Kelly Devine Deck B.S., CPA, M.S.	Executive VP & CFO	636.87k	N/A	1980
Mr. Quinn L. Deveraux	Founder	N/A	N/A	N/A
Dr. Ashraf Amanullah	Executive VP & Chief Technical Operations Officer	N/A	N/A	1968
Ms. Leah Pollema J.D.	VP, Corporate Secretary & General Counsel	N/A	N/A	N/A
Dr. Charbel Helaihel Pharm.D.	Vice President of Marketing & Commercial Planning	N/A	N/A	N/A
Mr. Jeffrey J. Jensen	Executive VP & Chief Clinical Operations Officer	N/A	N/A	N/A
Mr. David Matly M.B.A.	Executive VP and Chief Commercial & Business Development Officer	N/A	N/A	N/A
Dr. Carlos Bais Ph.D.	Executive Vice President of Translational Sciences	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Corporate governance

Inhibrx, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.